Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (January 2017)

26 slides from Enumeral Biomedical's investor presentation, Jan 9, 2017

  1. Slide 1: Translating biological complexity into more powerful therapeutics

    Translating biological complexity into more powerful therapeutics January 2017

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward - looking statements that are based on the company’s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no representations about the accuracy of such statemen

  3. Slide 3: Proprietary single cell 'microengraving' technology reveals novel disease insights

    Proprietary single cell ‘ microengraving ’ technology reveals novel and valuable disease insights 3 Chris Love Associate Professor of Chemical Engineering at the Koch Institute for Integrative Cancer Research at MIT

  4. Slide 4: Proprietary, functionalized microwell chip

    Proprietary, functionalized microwell chip 4

  5. Slide 5: Integrated system yields diverse types of data from one sample

    Integrated system yields diverse types of data from one sample, at the single cell resolution 5 Isolate Rapid isolation of complex mixtures into single cells • Several chips per sample, 84,000 wells per chip, ~1 cell per well • Starting sample can be blood, tissue or cultured cells, or a mixture • S

  6. Slide 6: Understanding disease at the single cell level facilitates precision medicine

    Understanding disease at the single cell level facilitates precision medicine 6 Single cell analysis reveals new disease insights New disease insights translate into better therapeutics

  7. Slide 7: ENUM past & present

    ENUM past & present 2017: Unlocking full technology potential 7 Exclusive license from MIT Differentiated, high affinity PD1 antibodies discovered Tim3 antibodies discovered Focused on securing partnerships to discover & develop novel therapeutics Technology partnership SBIR Phase II contract Techno

  8. Slide 8: Platform technology is automated and validated

    Platform technology is automated and validated 8 Industrialized, automated & validated (2011 - 16)

  9. Slide 9: Seeking partnerships to leverage the power of the technology

    Seeking partnerships to leverage the power of the technology 9 Autoimmune • Compare diseased vs. normal tissue at cellular resolution • Analysis of ectopic lymphoid - like structures Discover & validate new therapeutic targets Immune - oncology • Interrogate tumor microenvironment • Isolate and anal

  10. Slide 10: Questions we're being asked

    Questions we’re being asked 10 “Can you help us understand why patients don’t respond to our drug?” “How do tumors develop resistance to our therapy?” “Can you isolate the B cells that are making the antibodies that are protecting the patient from disease?” “I’m interested in tumor - associated macr

  11. Slide 11: Experienced, commercially pragmatic leadership team

    Experienced, commercially pragmatic leadership team 11 Wael Fayad Chairman, President and CEO Robert Schaub, Ph.D. Interim Head of Research and Development Kevin G. Sarney Vice President of Finance, Treasurer, and Chief Accounting Officer Matthew A. Ebert General Counsel

  12. Slide 12: Why partner with Enumeral?

    Why partner with Enumeral? • Validated and versatile technology • Technology enables discovery of next generation therapeutics • Partnerships are cornerstone of company strategy • Experienced management (partnerships and science) • Flexible deal structure and terms • Rapid, streamlined deal - making

  13. Slide 13: Case studies

    Case studies Translating biological complexity into more powerful therapeutics

  14. Slide 14: Discovery of new targets in the tumor microenvironment

    14 Discovery of new targets in the tumor microenvironment Recent clinical trials showed that targeting of inhibitory receptors on T cells induces durable responses in a subset of cancer patients, despite advanced disease. However, the regulatory switches controlling T cell function in immunosuppress

  15. Slide 15: Technology enables B-cell selection without hybridomas

    15 Technology enables B - cell selection without hybridomas , enabling broader and more diverse antibody libraries Monoclonal antibodies that recognize specific antigens of interest are used as therapeutic agents and as tools for biomedical research. Discovering a single monoclonal antibody requires

  16. Slide 16: Retrieval, expansion and characterization of single human CD8 T-cells

    16 Retrieval, expansion and characterization of single human CD8 T - cells, based on their ability to lyse a target cell CD8+ T cells are a key component of the adaptive immune response to viral infection. An inadequate CD8+ T cell response is thought to be partly responsible for the persistent chro

  17. Slide 17: Understanding the temporal dynamics of T-cell activation

    17 Understanding the temporal dynamics of T - cell activation at the single cell level The release of cytokines by T cells defines a significant part of their functional activity in vivo, and their ability to produce multiple cytokines has been associated with beneficial immune responses. To date, t

  18. Slide 18: Single cell profiling of diseased Crohn's vs. normal tissue

    Single cell profiling of diseased Crohn’s vs. normal tissue elucidated new therapeutic strategies 18 99% 1% Normal tissue, adjacent to diseased tissue: low expression Non-Secretors Secretors 0 20 40 60 80 100 120 IFN-g IL17 IFN-g/IL17 Cell Number Cytokine Active Crohn’s disease tissue Non-Secretors

  19. Slide 19: Imaging of IFN-g Secretion in Crohn's Disease

    Imaging of IFN - g Secretion in Crohn’s Disease 19 Active Crohn’s Disease Normal Adjacent Tissue

  20. Slide 20: PD-1 and TIM-3 are expressed in active Crohn's lesions

    PD - 1 and TIM - 3 are expressed in active Crohn’s lesions 20 0 20 40 60 80 100 120 IFN - g Secretion by Normal Adjacent vs. Active Crohn's Disease Normal Adjacent Active

  21. Slide 21: Increased percentage of TIM-3 and PD-1 expressing cells in Crohn's remission biopsy

    Increased percentage of TIM - 3 and PD - 1 expressing cells in Crohn’s remission biopsy 21 0.00 10.00 20.00 30.00 40.00 50.00 60.00 Percent of Total Cell Surface Phenotype Normal Adjacent Remission Cells from remission biopsy have undetectable level of secretion

  22. Slide 22: Total Cell Analysis of Melanoma Tumors: CD4+ cells

    Total C ell A nalysis of Melanoma Tumors : Identifies C o - E xpression of Immune Modulatory Receptors Associated with CD4+ and CD4 - Cells • Analysis of Cytokine Secretion in CD4 subset • 15,000 cells analyzed • Secretion seen in 15% of cells • TNF secretion comprises largest fraction of events; po

  23. Slide 23: Total Cell Analysis of Melanoma Tumors: CD8+ cells

    Total C ell A nalysis of Melanoma Tumors : Identifies C o - expression of Immune Modulatory Receptors with CD8 + and CD8 - Cells • Cytokine secretion in CD8 subset • 15,000 cells analyzed • Secretion seen in 17% of cells • TNF secretion comprises largest fraction of events; polyfunctional cells obse

  24. Slide 24: In-house antibody discovery program

    In - house antibody discovery program Discovering broad and diverse antibodies against targets of high interest

  25. Slide 25: Discovery of differentiated PD1 antibodies

    Discovery of differentiated PD1 antibodies 25 244C8 Binds a differentiated PD1 epitope • ENUM 244C8 antibody binds a distinct epitope, does not inhibit PDL binding, and maintains anti - tumor activity 388D4 Binds a similar PD - 1 epitope • ENUM 388D4 antibody binds a similar epitope, and has anti -

  26. Slide 26: Enumeral antibody pipeline (partnering opportunities)

    Enumeral antibody pipeline (partnering opportunities) 26 PD - 1 Antibody ENUM 244C8 PD - 1 Antibody ENUM 388D4 TIM - 3 Antibody CD39 Lead generation Screening Optimization / Differentiation Pre - Clinical IND Enabling IND Other targets Development Candidate

Enumeral Biomedical Holdings — Investor Presentation (January 2017) on 6ix